Prostatic Hyperplasia (Benign Prostatic Hyperplasia)

Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.

Also Known As:

Benign Prostatic Hyperplasia; Benign Prostatic Hypertrophy; Adenomas, Prostatic; Benign Prostatic Hyperplasias; Hyperplasia, Benign Prostatic; Hyperplasia, Prostatic; Hyperplasias, Benign Prostatic; Hypertrophies, Prostatic; Hypertrophy, Benign Prostatic; Hypertrophy, Prostatic; Prostatic Adenomas; Prostatic Hyperplasias, Benign; Prostatic Hypertrophies; Adenoma, Prostatic; Prostatic Adenoma; Prostatic Hyperplasia, Benign; Prostatic Hypertrophy; Prostatic Hypertrophy, Benign

Networked: 10271 relevant articles (902 outcomes, 1681 trials/studies)

Relationship Network

Disease Context: Research Results

Urogenital Diseases: 126
- Genital Diseases: 114
  - Male Genital Diseases: 2
    - Prostatic Diseases: 520
      - Prostatic Hyperplasia: 10271
        Prostatic stromal proliferation of uncertain malignant potential
- Male Urogenital Diseases
  - Male Genital Diseases: 2
    - Prostatic Diseases: 520
      - Prostatic Hyperplasia: 10271
        Prostatic stromal proliferation of uncertain malignant potential

Related Diseases

1.	Lower Urinary Tract Symptoms
2.	Prostatic Neoplasms (Prostate Cancer)
3.	Urinary Retention
4.	Overactive Urinary Bladder (Overactive Bladder)
5.	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)

Experts

1.	Kaplan, Steven A: 171 articles (02/2022 - 10/2002)
2.	Roehrborn, Claus G: 112 articles (01/2022 - 06/2002)
3.	McVary, Kevin T: 61 articles (01/2022 - 08/2002)
4.	Montorsi, Francesco: 36 articles (01/2020 - 03/2004)
5.	Viktrup, Lars: 32 articles (01/2019 - 10/2008)
6.	Chughtai, Bilal: 31 articles (10/2022 - 05/2005)
7.	Zorn, Kevin C: 28 articles (10/2022 - 10/2011)
8.	Te, Alexis E: 28 articles (01/2022 - 06/2002)
9.	Masumori, Naoya: 26 articles (09/2019 - 06/2002)
10.	Nickel, J Curtis: 25 articles (08/2021 - 09/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Prostatic Hyperplasia:

1.	Tamsulosin (Flomax)FDA LinkGeneric 01/01/2013 - "Tamsulosin hydrochloride is one of the most potent drugs for treatment of benign prostatic hyperplasia (BPH), however, the efficacy of tamsulosin hydrochloride varies among individuals. " 06/24/2009 - "Tamsulosin (0.3-300 microg/kg) also dose-dependently inhibited the intraurethral pressure increase in both groups, but it had a hypotensive effect that was significantly greater in old than in young dogs with benign prostatic hyperplasia. " 11/01/1998 - "Tamsulosin was safe and effective, and clinically and statistically superior to placebo in relieving symptoms of benign prostatic hyperplasia in men with moderate to severe symptoms at baseline. " 09/01/2017 - "The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"." 09/01/2017 - "Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"."
2.	Finasteride (Propecia)FDA LinkGeneric 11/01/2007 - "One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect. " 05/01/2009 - "A significantly greater proportion of patients using multiple medications and finasteride were adherent with any benign prostatic hyperplasia medication (62% and 55%, respectively, p <0.0001). " 01/01/1995 - "The total, obstructive and non-obstructive symptom scores decreased (improved) for patients on 1 and 5 mg finasteride, with the total score reducing by 33% from baseline at year 3. The results demonstrate that finasteride causes a modest but significant clinical improvement in men with urinary outflow obstruction secondary to benign prostatic hyperplasia." 07/24/2009 - "Finasteride is a mechanism-based inactivator of 5alpha-reductase type 2 with subnanomolar affinity and is widely used as a therapeutic for the treatment of benign prostatic hyperplasia. " 12/01/1999 - "Finasteride is widely used for the treatment of benign prostatic hyperplasia (BPH). "
3.	Tadalafil (Cialis)FDA Link 05/20/2023 - "However, the administration of a low dose of tadalafil for the patient's benign prostatic hyperplasia allowed for the increase in the dose of RAAS inhibitors and markedly improved his subjective symptoms and hemodynamics. " 01/01/2014 - "In dose-ranging and confirmatory studies, results demonstrate that tadalafil significantly improved total International Prostate Symptom Score (IPSS) following 12 weeks of treatment with once daily tadalafil 5 mg. Statistically significant improvements in Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS QOL and International Index of Erectile Function (IIEF) were also observed. " 09/01/2012 - "Once-daily tadalafil 5 mg was effective in treating the signs and symptoms of benign prostatic hyperplasia (BPH). " 09/05/2020 - "Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats." 05/01/2019 - "Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study."
4.	Dutasteride (Avodart)FDA Link 03/01/2014 - "Dutasteride is highly effective in mitigating benign prostatic hyperplasia symptoms and reducing the size of enlarged prostate and the risks of AUR and surgical intervention. " 09/01/2005 - "Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies." 01/01/2015 - "Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice." 01/01/2006 - "Dutasteride has subsequently been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomized, placebo-controlled, Phase III clinical studies lasting for 2 years. " 07/01/2015 - "[CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA]."
5.	alfuzosin (UroXatral)FDA Link 02/01/2013 - "The purpose of present research was to develop and optimize sustained release floating pellets of alfuzosin hydrochloride which has narrow absorption window in proximal intestine to improve patient compliance and therapeutic efficacy in the treatment of benign prostatic hyperplasia. " 01/01/2002 - "To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulation of the clinically uroselective alpha1-blocker, alfuzosin, in patients with symptomatic benign prostatic hyperplasia (BPH). " 12/01/2001 - "Alfuzosin 10 mg OD, administered without dose titration, provides effective relief from the symptoms of benign prostatic hyperplasia with no additional benefit from a 15-mg dose. " 11/01/1993 - "Alfuzosin is a new alpha 1-adrenoceptor antagonist particularly effective in the symptomatic treatment of benign prostatic hypertrophy (BPH). " 01/01/2002 - "Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study."
6.	Doxazosin (Cardura)FDA LinkGeneric 06/10/2005 - "These findings, that demonstrate chronic doxazosin administration causes significant changes in the expression of several hundred genes in the rat prostate, may provide insight into the long-term efficacy of alpha1-AR antagonists in the treatment of benign prostatic hyperplasia." 09/01/1996 - "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." 03/01/1994 - "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated. " 01/01/1993 - "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. " 10/01/2005 - "Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction."
7.	Testosterone (Sustanon)FDA Link 07/01/2023 - "There is a significant reduction in the serum testosterone concentration of benign prostatic hyperplasia patients, (4.05±3.1 ng/ml), as compared with control subjects, (11.37±2.87; p≤0.01). " 01/01/2023 - "This study was designed to investigate the protective effects of Calocybe indica extract on testosterone-induced benign prostatic hyperplasia in rats. " 10/03/2022 - "Afterwards, the testosterone-induced BPH model was used to verify the alleviation efficacy of CAA in prostatic hyperplasia. " 01/01/2022 - "Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats." 01/01/2019 - "Histopathological examination also showed that 20 nm but not the 50 nm AuNps administration ameliorates testosterone-induced prostatic hyperplasia. "
8.	silodosin FDA Link 01/01/2013 - "Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies." 06/01/2009 - "Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies." 05/07/2011 - "In men aged >50 years with benign prostatic hyperplasia (BPH), silodosin 8 mg once daily, compared with placebo, was associated with a significantly more rapid and effective improvement in the total International Prostate Symptom Score (IPSS) and the storage and voiding IPSS subscores in three 12-week, phase III trials conducted in Europe and the US. " 01/01/2011 - "The uroselective α-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ≥ 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. " 01/01/2010 - "Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective α-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). "
9.	naftopidilIBA 07/01/2004 - "The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). " 01/01/2006 - "We evaluated the efficacy of an alpha1a/d blocker, naftopidil, on storage symptoms in patients with benign prostatic hyperplasia (BPH), using frequency/volume charts (FVC). " 01/01/2020 - "Previous studies have indicated that α1D/1A antagonist naftopidil (NAF) suppresses prostate growth by decreasing cell proliferation without affecting apoptosis and prostate volume in benign prostatic hyperplasia (BPH). " 04/15/2021 - "Naftopidil (NAF), an α1-adrenoceptor antagonist, is administered as a treatment for benign prostatic hyperplasia; however, according to the Biopharmaceutical Classification System (BCS IV), it is a poorly-soluble drug that exhibits poor permeability. " 01/01/2020 - "This strategy allowed a renewed interest for Naftopidil, an α1-adrenergic receptor antagonist commercialized in Japan for benign prostatic hyperplasia. "
10.	Terazosin (Hytrin)FDA LinkGeneric 12/01/1988 - "The results at four months of a six-month study support the conclusion that terazosin is beneficial for treatment of symptoms in patients with benign prostatic hypertrophy." 10/01/1989 - "These preliminary results confirm that terazosin significantly improved peak as well as mean urine flow rates and significantly reduced residual volume and significantly improved obstructive symptoms in patients with benign prostatic hyperplasia (p less than 0.001). " 01/01/1992 - "Terazosin was found to be safe and effective in the dose range of 2-20 mg taken at bedtime in men with symptoms related to benign prostatic hyperplasia. " 03/01/1996 - "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH). " 03/01/1996 - "A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia."

Therapies and Procedures

1.	Transurethral Resection of Prostate (TURP) 04/01/2021 - "Surgery is considered the most effective treatment for Benign prostatic hyperplasia (BPH) and Transurethral resection of prostat (TURP) is considered the gold standard. " 05/01/1993 - "Transurethral resection of the prostate (TURP) is the most effective treatment for prostatic obstruction secondary to benign prostatic hyperplasia (BPH). " 04/01/2020 - "Although the conventional, monopolar transurethral resection of the prostate (TURP) has proven to be an effective and relatively safe treatment for patients with benign prostatic hyperplasia (BPH), many new endoscopic technologies have been introduced to treat BPH. " 09/03/1997 - "[Transurethral thermotherapy of the prostate--a very promising treatment method for benign prostatic hyperplasia]." 01/01/2022 - "This study aims to compare the efficacy of plasma kinetic loop resection of the prostate (PKRP) and transurethral vaporization of the prostate (TUVP) for the treatment of high-risk benign prostatic hyperplasia (BPH), and analyze the influence of the related factors on the operation of BPH. "
2.	Therapeutics 05/01/2013 - "Active surveillance of very-low-risk PCa in the setting of 5-ARI therapy for benign prostatic hyperplasia appears to be a safe therapeutic option, because most (57 of 82; 70%) patients maintained very-low-risk PCa or had negative follow-up biopsies during a 3-year follow-up period. " 01/01/2003 - "Medical therapy is now the first-line treatment for most men with symptomatic benign prostatic hyperplasia. " 01/01/2020 - "Convective radio frequency thermal therapy with the Rezūm® system is a relatively new treatment for benign prostatic hyperplasia with proven short-term durability. " 08/01/2012 - "The currently available endourological treatments, transurethral resection of the prostate, and PKRP, are safe and effective therapies for treating aged high-risk patients with benign prostatic hyperplasia (BPH), although PKRP is superior in many aspects, including perioperative outcomes." 03/01/1997 - "Overall, while surgery still holds the gold standard, medical therapy has a significant role in the treatment of benign prostatic hypertrophy. "
3.	Solid-State Lasers 01/01/2022 - "Abstract Introduction and Objectives: Holmium laser enucleation of the prostate (HoLEP) is a highly effective treatment of benign prostatic hyperplasia (BPH). " 08/01/2010 - "Holmium laser enucleation of the prostate is highly effective for symptomatic benign prostatic hyperplasia. " 09/01/2008 - "Holmium laser enucleation of the prostate is the single best treatment for benign prostatic hyperplasia refractory to medication." 11/01/2006 - "Photoselective vaporization of the prostate (PVP) using the high power (80 W) potassium-titanyl-phosphate laser for benign prostatic hyperplasia (BPH) proved to be an effective and safe procedure for our patients." 01/01/2011 - "Holmium laser enucleation of the prostate is superior to other modalities for the treatment of benign prostatic hyperplasia. "
4.	Lasers (Laser) 01/01/2015 - "Photoselective vaporization of the prostate (PVP) using the new 180-W XPS GreenLight laser system seems to be a safe and effective procedure and could play an important role in the surgical treatment of symptomatic benign prostatic hyperplasia (BPH) patients with larger prostate volumes." 01/01/2013 - "The use of lasers to perform photoselective vaporization of the prostate (PVP) has been widely accepted as a safe and effective treatment for benign prostatic hyperplasia with very few reported complications. " 04/01/2011 - "With the use of 12 months of follow-up data, this study was conducted to evaluate the efficacy of photoselective vaporization of the prostate (PVP) with the 120 W Greenlight high performance system (HPS) laser for the treatment of symptomatic benign prostatic hyperplasia. " 06/01/2020 - "Purpose: To evaluate the safety and efficacy of GreenLight XPS 180-W laser photoselective vaporization of the prostate (PVP) in high-risk elderly patients with benign prostatic hyperplasia. " 05/01/2015 - "Efficacy of a vaporization-resection of the prostate median lobe enlargement and vaporization of the prostate lateral lobe for benign prostatic hyperplasia using a 120-W GreenLight high-performance system laser: the effect on storage symptoms."
5.	Prostatectomy (Retropubic Prostatectomy) 05/01/2014 - "Robot-assisted simple prostatectomy is a safe and effective operation for benign prostatic hyperplasia, which can be learned with good results in a rather short time." 01/01/1997 - "Free and complexed PSA have different clearances and significant differences between clearance of free PSA after radical prostatectomy (RP) and after open surgery for benign prostatic hyperplasia (BPH) are observed. " 10/01/1990 - "Whilst prostatectomy remains the "gold standard" for the treatment of outflow tract obstruction due to benign prostatic hyperplasia, medical treatment--if only for symptomatic relief--appears to be an attractive alternative. " 09/01/2021 - "Editorial Comment for the paper entitled "Robotic simple prostatectomy is safe and effective technique for benign prostatic hyperplasia: Our single center initial results for 42 patients"." 07/01/2021 - "Robotic simple prostatectomy is a safe and effective technique for benign prostatic hyperplasia: Our single center initial short-term follow-up results for 42 patients."